Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Indian’s big pharma companies finding new growth opportunities in China, a market set to be worth US$209bn by 2022, says GlobalData

Indian pharmaceutical companies are finding lucrative opportunities for growth in the Chinese pharma market, which is set to rise from nearly US$132bn in 2018 to more than US$209bn by 2022, says GlobalData, a leading data and analytics company. Prashant Khadayate, Pharma Analyst at GlobalData, comments: “The Chinese pharma market is the second largest pharma market […]
Read more

Global B-cell NHL market set to reach $9.2bn by 2027

The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 4.9%, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to […]
Read more

Global post-traumatic stress disorder market set to reach US$1.2bn by 2028

The total post-traumatic stress disorder market was estimated to be worth US$211.4m across the seven major markets (7MM*) in 2018. This is expected to grow at a compound annual growth rate (CAGR) of 18.7% to reach US$1.2bn by 2028, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Post-Traumatic Stress Disorder (PTSD): […]
Read more

Global spinal muscular atrophy market set to reach US$6.6bn in 2028

The total spinal muscular atrophy (SMA) market was estimated to be worth US$1.5bn across the seven major markets (7MM*) in 2018. This is expected to grow to US$6.6bn in 2028, at an impressive compound annual growth rate (CAGR) of 16%, according to GlobalData, a leading data and analytics company. GlobalData’s latest report: ‘Spinal Muscular Atrophy […]
Read more

Governments must showcase potential of HPV vaccines in cervical cancer to fight vaccine hesitancy

Following the latest research published in The Lancet highlighting the potential impact HPV vaccinations could have on cervical cancer rates, James Mather, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Research continues to demonstrate that population-wide impact of Human papillomavirus (HPV) vaccinations is significantly reducing the prevalence of HPV. […]
Read more

Dupixent boost from FDA approval will see drug achieve blockbuster status in 2019 and estimated sales of $6.4bn in 2025

Following the news that the FDA has approved Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis, Philippa Salter, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dupixent is the first biologic to be approved for the treatment of chronic rhinosinusitis with nasal polyposis, beating rivals in gaining market approval […]
Read more

Lack of reimbursement will limit the impact of digital therapeutics in global healthcare market

A major barrier to the widespread use of digital therapeutics (DTx) is the limitation or lack of reimbursement by public and private health insurance providers, says GlobalData, a leading data and analytics company. Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are […]
Read more

Roche’s Xofluza shows promise in flu prevention

Following the recent news that Roche’s Phase III influenza drug Xofluza met its primary endpoint for influenza prevention, Philipp Rosenbaum, Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “Given that seasonal influenza vaccines were only around 45% effective over the past 10 influenza seasons, a prophylactic label expansion for Xofluza could […]
Read more

Novavax’s ResVax at risk of losing first-to-market lead in RSV vaccines

Following the recent news that the FDA has recommended an additional Phase III trial for Novavax’s vaccine to prevent medically significant RSV disease in infants, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “After a string of late-stage clinical disappointments in trials of both elderly adults and pregnant […]
Read more

Following NICE recommendation, Prevymis set to exceed $5.6m peak year sales in UK

Following the recent news that NICE has recommended Merck’s Prevymis for preventing cytomegalovirus (CMV) reactivation in recipients of hematopoietic stem cell transplantation (HSCT), Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “NICE’s revised recommendation is a major commercial win for Merck that will allow Prevymis to be funded […]
Read more
1 … 104 105 106 107 108